BlossomHill Therapeutics (BLSM) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($543.5 million vs $540.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | NGNE |
|---|---|---|
| Share price | $17.10 | $27.01 |
| Market cap | $543.52M | $540.41M |
| 1-day change | +1.30% | +1.91% |
| YTD return | — | +28.64% |
| 1-year return | — | +2.59% |
| 5-year return | — | -81.65% |
| EPS (TTM) | $-4.70 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $43.66 |
| 52-week low | $15.25 | $15.93 |
| Distance from 52-week high | -38.91% | -38.15% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +107.02% | +188.39% |
| Average volume | 261.23K | 247.13K |
| Shares outstanding | 31.78M | 20.01M |
| Employees | 69 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
BLSM vs NGNE FAQ
Which is bigger, BlossomHill Therapeutics or Neurogene?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $543.52M compared with $540.41M for Neurogene (NGNE).
Are BlossomHill Therapeutics and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.